Alnylam spotlights just how good the efficacy data are for givosiran — tamping down on safety concerns
Alnylam $ALNY took another turn on its transition lap to a fully fledged commercial biotech today, posting its detailed — and very promising — efficacy data for their RNAi drug givosiran while hoping to tamp down the fretting over safety issues that spoiled their earlier top-line announcement.
We knew going into the European Association for the Study of the Liver meeting in Vienna that the drug had a great p value — now backed up by a 90% median reduction in attacks of acute hepatic porphyria, a painful and debilitating illness with no currently approved therapies. Half of the patients ended attack free, which would make this a no-brainer for regulators.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.